MARKET

NMRA

NMRA

Neumora Therapeutics Inc
NASDAQ
1.840
-0.130
-6.60%
After Hours: 1.820 -0.02 -1.09% 18:17 05/15 EDT
OPEN
1.940
PREV CLOSE
1.970
HIGH
1.955
LOW
1.830
VOLUME
829.24K
TURNOVER
--
52 WEEK HIGH
3.650
52 WEEK LOW
0.6110
MARKET CAP
340.92M
P/E (TTM)
-1.3869
1D
5D
1M
3M
1Y
5Y
1D
SoftBank exits Circle Internet, Uber; cuts stake in T-Mobile among top Q1 moves
Seeking Alpha · 1d ago
Ami Fadia Reiterates Buy on Neumora, Sees Compelling Risk-Reward Ahead of Phase 3 Readouts with Unchanged $8 Price Target
TipRanks · 2d ago
Neumora Therapeutics to join RBC Capital Markets Global Healthcare Conference fireside chat
PUBT · 4d ago
Analysts Offer Insights on Healthcare Companies: Mettler-Toledo (MTD) and Neumora Therapeutics, Inc. (NMRA)
TipRanks · 4d ago
Analysts Offer Insights on Healthcare Companies: Neumora Therapeutics, Inc. (NMRA), Biomea Fusion (BMEA) and Adaptive Biotechnologies (ADPT)
TipRanks · 4d ago
Weekly Report: what happened at NMRA last week (0504-0508)?
Weekly Report · 5d ago
Analysts’ Top Healthcare Picks: Siemens Healthineers AG (SEMHF), Neumora Therapeutics, Inc. (NMRA)
TipRanks · 05/09 01:50
Neumora's Pipeline Credibility Rests on Two Readouts Due Within Weeks
Barchart · 05/08 16:08
More
About NMRA
Neumora Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company's therapeutic pipeline consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its advanced product candidate, navacaprant (NMRA-140), is a novel once-daily oral kappa opioid receptor (KOR) antagonist that is being developed for the treatment of depressive disorder (MDD). Navacaprant is being investigated in the KOASTAL pivotal Phase 3 program, evaluating navacaprant monotherapy in patients with moderate to severe MDD. The Company's next advanced product candidate is NMRA-511, which is a highly selective, novel antagonist of the vasopressin 1a receptor (V1aR) being developed for the treatment of agitation associated with dementia due to Alzheimer's disease (AD).

Webull offers Neumora Therapeutics Inc stock information, including NASDAQ: NMRA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NMRA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NMRA stock methods without spending real money on the virtual paper trading platform.